Among the TKIs approved for CML treatment in the USA and EU—imatinib, dasatinib, nilotinib, bosutinib, ponatinib, and asciminib—imatinib is the only one whose absorption depends on both influx (e.g., OCTN2, OATP1A2, OCT1) and efflux (e.g., ABCB1, ABCG2) transporters. This evidence concerns the gene SLC22A5 and chronic myelogenous leukemia, BCR-ABL1 positive.